Tags

Type your tag names separated by a space and hit enter

Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy.
Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1668-73.CE

Abstract

In this study we determined urine concentration of the tobacco alkaloids anabasine and anatabine, nicotine and its metabolites cotinine, and nornicotine in 99 cigarette smokers and 205 smokeless tobacco users. We also investigated the possibility that anabasine and anatabine can be used as biomarkers for tobacco use during nicotine replacement therapy. Urine samples and data on self-reported tobacco use were obtained from subjects enrolled in tobacco cessation programs. Urine concentrations of tobacco alkaloids and metabolites were measured and correlated with self-reported tobacco use. Concentrations of anabasine and anatabine were used to validate abstinence in smokeless tobacco users who used nicotine gum as part of the therapy. Correlations of alkaloid concentration with self-reported tobacco use before treatment ranged from fair to poor. In subjects abstaining from smokeless tobacco but using nicotine gum, anabasine and anatabine levels were below the cut-point of 2 ng/ml despite high concentrations of nicotine and cotinine resulting from nicotine gum use. Anabasine and anatabine concentrations in urine can be used to validate abstinence or measure the extent of tobacco use in persons undergoing nicotine replacement therapy.

Authors+Show Affiliations

Jacob P
Division of Clinical Pharmacology, San Francisco General Hospital Medical Center, Department of Medicine, University of California, San Francisco, San Francisco, California 94110, USA. peyton@itsa.ucsf.edu
Hatsukami D
No affiliation info available
Severson H
No affiliation info available
Hall S
No affiliation info available
Yu L
No affiliation info available
Benowitz NL
No affiliation info available

MeSH

AdultAlkaloidsAnabasineBiomarkersChewing GumFemaleFollow-Up StudiesHumansMaleMiddle AgedNicotineProbabilityProspective StudiesPyridinesReference ValuesSensitivity and SpecificitySeverity of Illness IndexSmokingTobacco Use CessationTobacco Use DisorderTobacco, SmokelessTreatment Outcome

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12496059

Citation

Jacob, Peyton, et al. "Anabasine and Anatabine as Biomarkers for Tobacco Use During Nicotine Replacement Therapy." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 11, no. 12, 2002, pp. 1668-73.
Jacob P, Hatsukami D, Severson H, et al. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1668-73.
Jacob, P., Hatsukami, D., Severson, H., Hall, S., Yu, L., & Benowitz, N. L. (2002). Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 11(12), 1668-73.
Jacob P, et al. Anabasine and Anatabine as Biomarkers for Tobacco Use During Nicotine Replacement Therapy. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1668-73. PubMed PMID: 12496059.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. AU - Jacob,Peyton,3rd AU - Hatsukami,Dorothy, AU - Severson,Herbert, AU - Hall,Sharon, AU - Yu,Lisa, AU - Benowitz,Neal L, PY - 2002/12/24/pubmed PY - 2003/4/5/medline PY - 2002/12/24/entrez SP - 1668 EP - 73 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol Biomarkers Prev VL - 11 IS - 12 N2 - In this study we determined urine concentration of the tobacco alkaloids anabasine and anatabine, nicotine and its metabolites cotinine, and nornicotine in 99 cigarette smokers and 205 smokeless tobacco users. We also investigated the possibility that anabasine and anatabine can be used as biomarkers for tobacco use during nicotine replacement therapy. Urine samples and data on self-reported tobacco use were obtained from subjects enrolled in tobacco cessation programs. Urine concentrations of tobacco alkaloids and metabolites were measured and correlated with self-reported tobacco use. Concentrations of anabasine and anatabine were used to validate abstinence in smokeless tobacco users who used nicotine gum as part of the therapy. Correlations of alkaloid concentration with self-reported tobacco use before treatment ranged from fair to poor. In subjects abstaining from smokeless tobacco but using nicotine gum, anabasine and anatabine levels were below the cut-point of 2 ng/ml despite high concentrations of nicotine and cotinine resulting from nicotine gum use. Anabasine and anatabine concentrations in urine can be used to validate abstinence or measure the extent of tobacco use in persons undergoing nicotine replacement therapy. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/12496059/Anabasine_and_anatabine_as_biomarkers_for_tobacco_use_during_nicotine_replacement_therapy_ DB - PRIME DP - Unbound Medicine ER -